Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Seven more lung cancer drugs have been added to the interaction checker

Tuesday 03 May 2022

Brigatinib, capmatinib, crizotinib, dacomitinib, erlotinib, lorlatinib and selpercatinib are now listed in the interaction checker as cancer drugs and interactions can be found with all comedications.

  • Brigatinib (Alunbrig®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Capmatinib (Tabrecta®) is a HGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Crizotinib (Xalkori®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Dacomitinib (Vizimpro®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Erlotinib (Tarceva®) is an EGFR tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Lorlatinib (Lorbena®, Lorviqua®) is an ALK tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer.
  • Selpercatinib (Retevmo®) is a RET+ tyrosine kinase inhibitor and is indicated for the treatment of non-small cell lung cancer and medullary thyroid cancer.


ENDORSED BY
Bopa Esop gro%c3%9f %28resized%29